Researchers are reporting that early rapid improvements in the signs and symptoms of axial spondyloarthritis in patients treated with certolizumab pegol are maintained at 4 years.
Skeleton with back pain
Axial spondyloarthritis is characterized by inflammation of the sacroiliac joins and spine, which results in chronic back pain.

Dr. Desiree van der Heijde, with Leiden University Medical Centre in the Netherlands, and colleagues elsewhere examined outcomes at week 204 in patients who were randomized to certolizumab pegol or placebo as part of the phase III RAPID-axSpA trial.

Visit Original Source